Skip to main content
. 2024 Feb 8;8(1):102342. doi: 10.1016/j.rpth.2024.102342

Figure 2.

Figure 2

Immune thrombocytopenia (ITP)–related clinical characteristics of patients with thrombosis. (A and B) Bar graph showing the percentage of patients with thrombosis (A) at the ITP phase of diagnosis and (B) demonstrable ITP disease response. ITP phase was defined as the duration of ITP: chronic: >12 months; persistent: 3-12 months; and new <3 months. ITP disease response was defined as relapsed/refractory: platelet count < 30 × 109/L and requiring therapy; partial response: platelet count > 30 × 109/L in response to therapy and in the absence of rescue therapy; complete response: platelet count > 100 × 109/L in response to therapy and in the absence of rescue therapy. (C) Data showing the percentage of patients on concomitant ITP therapy at thrombosis diagnosis. Corticosteroids included prednisolone or dexamethasone, and other immune therapy included mycophenolate, hydroxychloroquine, rituximab, and azathioprine. (D) Data showing the percentage of patients with thrombosis risk factors at thrombosis diagnosis. CVA, cerebral vascular accident; IHD, ischemic heart disease; IVIG, intravenous immunoglobulin; TPO, thrombopoietin; VTE, venous thromboembolism. ∗Provoked VTE (transient major risk factor) = major surgery >30 minutes, hospitalization or immobilization for >2 days.